Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8NMAV)

• Drug Name: 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine Drug Info
• Synonyms: CHEMBL521211; 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine; BDBM50270649

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 24857857
  TTD Drug ID: DM8NMAV

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.5 (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[2]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[3]
Fosphenytoin	DMOX3LB	Epilepsy	8A60-8A68	Approved	[2]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[3]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[4]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[5]
Dyclonine	DMU6OFP	Pain	MG30-MG3Z	Approved	[6]
Moricizine	DMOMBJW	Arrhythmia	BC9Z	Approved	[7]
Ethotoin	DMXWOCP	Complex partial seizure	8A68.0	Approved	[8]
Prilocaine	DMI7DZ2	Pain	MG30-MG3Z	Approved	[6]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.8 (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[9]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[10]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[10]
Tiapride	DMN6CAG	Alcohol dependence	6C40.2	Approved	[11]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[12]
Proparacaine	DMLS39E	Anaesthesia	9A78.6	Approved	[10]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[13]
VX-150	DMGDB21	Neuropathic pain	8E43.0	Phase 2	[14]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[15]
PF-01247324	DM93LMS	Pain	MG30-MG3Z	Phase 1	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Inhibitor	[1]

References

• [1] Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem. 2008 Jun 15;16(12):6379-86.
• [2] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [3] Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
• [4] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [5] Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
• [6] Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
• [7] From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
• [8] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [9] Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [11] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [12] Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
• [13] Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [16] Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.